Video

First-Line Lymphoma Treatments

Publish date: December 18, 2009

 

Bendamustine plus rituximab has the potential to replace standard CHOP chemotherapy plus rituximab in the first-line treatment of advanced lymphomas. Dr. Mathias J. Rummel discusses data presented at the annual meeting of the American Society of Hematology.

Recommended Reading

Lymphoma and Biologics
MDedge Hematology and Oncology
Survival improves for AYAs with leukemia and lymphoma
MDedge Hematology and Oncology
Novel agent more effective than standard therapy in NHL
MDedge Hematology and Oncology
Potential cause of R-CHOP failure ruled out
MDedge Hematology and Oncology
Ofatumumab receives accelerated approval from FDA
MDedge Hematology and Oncology
Panobinostat shows promise in refractory Hodgkin lymphoma
MDedge Hematology and Oncology
Vorinostat demonstrates consistent safety
MDedge Hematology and Oncology
Most effective first-line therapy for T-PLL
MDedge Hematology and Oncology
Fostamatinib successfully targets the B-cell receptor
MDedge Hematology and Oncology